Sonavex files Form D for $15 million equity offering
The Baltimore biotech has raised roughly $3.1 million so far from five investors, with over $11.8 million still to be sold.
Sonavex, Inc., a Baltimore, Maryland based biotechnology company, filed a Form D notice with the Securities and Exchange Commission dated July 28, 2026, disclosing a new equity offering. The filing marks a new notice with a date of first sale listed as July 13, 2026.1
The total offering amount is set at $15,000,000, with $3,102,995 already sold and $11,897,005 remaining to be sold.1 Five investors have already put money into the offering.1
The company indicated it intends the offering to last more than one year.1 The securities being offered are classified as equity.1 The offering relies on an exemption under Rule 506(b)1 of Regulation D.
The filing states that this offering is not being made in connection with a transaction the form describes as a "business combination transaction, such as a merger, acquisition or exchange offer." Sonavex marked "No" in response to that question.1
The company estimated that $400,000 of the gross proceeds would go to payments for executive officers, directors, or promoters named in the filing.1 No sales commissions or finders' fees were reported.1
Sonavex classified its industry as biotechnology within the health care sector.1 The filing lists David Narrow, Devin O'Brien-Coon, Alex Yevzlin, William Niland, Robert Hallenbeck, Evan Pritchard, and Michael J. Hennessy, Jr. as related persons in executive officer, director, or promoter roles.1 David Narrow, identified as Chief Executive Officer, signed the notice on behalf of the issuer on July 28, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.